Demographic and clinical variables according to HIV infection status.

<p><b>SD</b>: standard deviation <b>IR</b>: 25–75% interquartile range <b>VL</b>: visceral leishmaniasis.</p>#<p>measured on physical examination at the left midclavicular line.</p>§<p>measured on physical examination at the right midclavicular line.</p><p><b>Hepatosplenomegaly</b>: palpable spleen or liver 2 cm over the right costal margin, as measured on physical examination <b>Cytopenia</b>: the presence of hemoglobin below 12 g% or a leukocyte count of less than 3500 cells/mm³ or a platelet count of less than 120000 cells/mm³<b>GOT:</b> glutamate oxaloacetate transaminases</p

Factors associated with a poor outcome in VL (at 6 months after VL diagnosis) in the univariate analysis.

<p><b>VL</b>: visceral leishmaniasis <b>IR</b>: 25–75% interquartile range.</p>§<p>in all cases, refers to the use of inhaled drugs derived from cocaine.</p

Treatment and outcomes according to HIV infection status.

<p><b>VL</b>: visceral leishmaniasis <b>Fever response</b>: the disappearance of fever at the end of treatment <b>Hemoglobin response</b>: patients presenting an increase of 2 g% or more in hemoglobin tax at the end of treatment <b>Leukocyte response</b>: patients presenting an increase of 50% or more in their leukocyte count at the end of treatment <b>Platelet response</b>: patients presenting an increase of 50% or more in their platelet count at the end of treatment <b>Spleen response</b>: a 2 cm or more reduction in spleen size palpation at the end of treatment <b>Clinical cure:</b> no death, recurrence, hepatosplenomegaly or hematological abnormalities <b>IR</b>: 25–75% interquartile range.</p

Factors associated with early death (within 1 month after VL diagnosis) from visceral leishmaniasis (univariate analysis).

<p><b>Severe neutropenia: a</b> neutrophil count of less than 500 cells/mm³<b>Severe thrombocytopenia: a</b> platelet count of less than 50000 cells/mm³.</p

Variables that remained in the final logistic regression model and were associated with a poor outcome in VL (at 6 months after VL diagnosis).

<p>Hosmer-Lemeshow goodness-of-fit test. p = 0.24.</p

Treatment switching and adverse events observed during initial drug treatment of VL.

<p>Treatment switching and adverse events observed during initial drug treatment of VL.</p